Managing risks of TNF inhibitors: an update for the internist.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24493494.
- Also identified by DOI 10.3949/ccjm.81a.12121.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor necrosis factor (TNF) inhibitors have many beneficial effects, but they also pose infrequent but significant risks, including serious infection and malignancy. These risks can be minimized by judicious patient selection, appropriate screening, careful monitoring during treatment, and close communication between primary care physicians and subspecialists.
Medical subject headings
- Antirheumatic Agents
- Dermatologic Agents
- Gastrointestinal Agents
- Infections
- Neoplasms
- Tumor Necrosis Factor-alpha